GeneDx Holdings Corp. (WGS) financials: revenue, earnings and cash flow
Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
GeneDx Holdings’s revenue went from $196M in fiscal 2019 to $428M in fiscal 2025, growth of about 13.9% a year.
Net income in fiscal 2025 was -$21M, a net margin of -4.9%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $461M and net income -$111M.
Free cash flow was $14M in fiscal 2025 and positive in 1 of the 7 years shown.
The diluted share count rose 762239595% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $461M | $428M | $305M | $203M | $235M | $212M | $179M | $196M |
| Gross profit | $317M | $298M | $194M | $90M | -$27M | -$17M | $4M | $83M |
| Operating income | -$100M | -$13M | -$23M | -$181M | -$668M | -$446M | -$242M | -$30M |
| Net income | -$111M | -$21M | -$52M | -$176M | -$549M | -$245M | -$241M | -$30M |
| EPS (diluted) | $-3.78 | $-0.73 | $-1.94 | $-7.23 | $-53.63 | $-74.91 | $-1552188.00 | $-8713848.00 |
| R&D | $81M | $72M | $46M | $58M | $86M | $105M | $73M | $35M |
| Revenue growth | — | +40.0% | +50.8% | −13.7% | +10.6% | +18.3% | −8.6% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$75M | $33M | -$28M | -$180M | -$319M | -$190M | -$93M | -$19M |
| Capital spending | -$26M | -$19M | -$5M | -$5M | -$7M | -$9M | -$24M | -$12M |
| Free cash flow | -$101M | $14M | -$34M | -$185M | -$326M | -$200M | -$117M | -$31M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — |
| Stock-based pay | $33M | $32M | $9M | -$326000 | $42M | $219M | $120M | $5M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash | — | $171M | $141M | $130M | $124M | $401M | $108M | $115M |
| Debt | — | $97M | $101M | $103M | $58M | $11M | $21M | — |
| Equity | — | $308M | $245M | $228M | $254M | $388M | -$330M | -$89M |
| Total assets | — | $524M | $419M | $419M | $491M | $554M | $252M | — |
| Shares (diluted) | 30M | 29M | 27M | 24M | 10M | 3M | 0M | 0M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 68.7% | 69.7% | 63.6% | 44.4% | -11.4% | -7.8% | 2.2% | 42.2% |
| Operating margin | -21.6% | -3.1% | -7.6% | -89.1% | -284.5% | -210.2% | -134.9% | -15.5% |
| Net margin | -24.1% | -4.9% | -17.1% | -86.8% | -233.9% | -115.6% | -134.6% | -15.1% |
| FCF margin | -22.0% | 3.3% | -11.1% | -91.5% | -139.0% | -94.2% | -65.4% | -15.6% |
| ROIC | — | -3.2% | -6.7% | -54.3% | -196.7% | -111.8% | — | — |
| ROE | — | -6.8% | -21.3% | -77.1% | -216.4% | -63.2% | 73.1% | 33.5% |
Frequently asked questions
What is GeneDx Holdings’s annual revenue?
$428M in fiscal 2025 and $461M over the twelve months to September 30, 2026.
How much profit does GeneDx Holdings make?
Net income was -$21M in fiscal 2025 (net margin -4.9%).
Is GeneDx Holdings’s revenue growing?
Yes: revenue rose 40.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.